350 related articles for article (PubMed ID: 35058882)
1. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
2. Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition.
Viho EMG; Kroon J; Feelders RA; Houtman R; van den Dungen ESR; Pereira AM; Hunt HJ; Hofland LJ; Meijer OC
J Endocrinol; 2023 Feb; 256(2):. PubMed ID: 36445262
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
4. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.
Regazzo D; Mondin A; Scaroni C; Occhi G; Barbot M
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742910
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
Sato A; Hara Y
Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
[TBL] [Abstract][Full Text] [Related]
8. New types of localization methods for adrenocorticotropic hormone-dependent Cushing's syndrome.
Senanayake R; Gillett D; MacFarlane J; Van de Meulen M; Powlson A; Koulouri O; Casey R; Bashari W; Gurnell M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101513. PubMed ID: 34045044
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
11. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
12. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
[TBL] [Abstract][Full Text] [Related]
13. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
[TBL] [Abstract][Full Text] [Related]
14. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN; Greenstein AE; Fleming GF; Borazanci E; Sharma MR; Custodio JM; Tudor IC; Pashova HI; Shepherd SP; Grauer A; Sachdev JC
Clin Cancer Res; 2022 Aug; 28(15):3214-3224. PubMed ID: 35583817
[TBL] [Abstract][Full Text] [Related]
16. Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenomas: An Underestimated Entity.
Knappe UJ; Jaspers C; Buschsieweke D; Reinbold WD; Alomari A; Saeger W; Ehlenz K; Mann WA; Kann PH; Feldkamp J
Neurosurgery; 2017 Apr; 80(4):525-533. PubMed ID: 27352274
[TBL] [Abstract][Full Text] [Related]
17. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
18. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Pivonello R; Bancos I; Feelders RA; Kargi AY; Kerr JM; Gordon MB; Mariash CN; Terzolo M; Ellison N; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():662865. PubMed ID: 34335465
[TBL] [Abstract][Full Text] [Related]
19. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
20. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]